	US 12,076,305 B2
	Compositions comprising a conjugate of quinic acid with caffeic acid, cosmetic and therapeutic uses
Iain William George Forbes, Edinburgh Lothian (GB); and William Forbes, Edinburgh Lothian (GB)
Assigned to CALSCIENCE INTERNATIONAL LTD, Edinburgh (GB)
Appl. No. 15/025,105
Filed by CALSCIENCE INTERNATIONAL LTD, Edinburgh (GB)
PCT Filed Sep. 19, 2014, PCT No. PCT/GB2014/052863 § 371(c)(1), (2) Date Mar. 25, 2016, PCT Pub. No. WO2015/044649, PCT Pub. Date Apr. 2, 2015.
Claims priority of application No. 1317286 (GB), filed on Sep. 30, 2013.
Prior Publication US 2016/0228394 A1, Aug. 11, 2016
Int. Cl. A61K 31/216 (2006.01); A01N 1/02 (2006.01); A61K 8/37 (2006.01); A61K 8/9789 (2017.01); A61K 8/9794 (2017.01); A61K 36/28 (2006.01); A61K 45/06 (2006.01); A61K 47/55 (2017.01); A61Q 7/00 (2006.01); A61Q 19/00 (2006.01); A61Q 19/06 (2006.01); A61Q 19/08 (2006.01)

CPC A61K 31/216 (2013.01) [A01N 1/0205 (2013.01); A61K 8/37 (2013.01); A61K 8/375 (2013.01); A61K 8/9789 (2017.08); A61K 8/9794 (2017.08); A61K 36/28 (2013.01); A61K 45/06 (2013.01); A61K 47/55 (2017.08); A61Q 7/00 (2013.01); A61Q 19/00 (2013.01); A61Q 19/06 (2013.01); A61Q 19/08 (2013.01)]

22 Claims

1. A method for the amelioration and/or treatment of disorders and diseases involving pre-mature, induced, or accelerated cell, tissue, or organ senescence comprising:

administering a composition to a subject having pre-mature, induced, or accelerated senescence associated degeneration in cells, tissues and/or organs, wherein the composition comprises:

(a) 1,4-dicaffeoylquinic acid or 3,4,5-tricaffeoylquinic acid or an isomer or salt thereof and (b) at least one acceptable carrier,

wherein the disorders and diseases are osteoporosis, osteopenia, periodontitis, intervertebral disc degeneration, side effects of radiotherapy, side effects of chemotherapy, alopecia, progeria, prostate cancer, breast cancer, stroke, atherosclerosis, or arteriosclerosis.